Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial
BackgroundThe CIAO trial recently demonstrated a probable clinical benefit of omalizumab in the treatment of severe COVID-19; however, the mechanism underlying this benefit remains unclear. Therefore, we sought to longitudinally assess the impact of omalizumab on serum cytokines in CIAO trial patien...
Saved in:
| Main Authors: | Connor Prosty, Michelle Le, Yang Lu, Lauren Khoury, Maxime Cormier, Mathew P. Cheng, Robert Fowler, Srinivas Murthy, Jennifer LY Tsang, Duncan Lejtenyi, Moshe Ben-Shoshan, Elham Rahme, Shirin Golchi, Nandini Dendukuri, Todd C. Lee, Elena Netchiporouk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1437322/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria
by: Luis Felipe Ensina, et al.
Published: (2025-01-01) -
Rapid food desensitization associated with omalizumab before oral immunotherapy
by: Bruna Giavina-Bianchi, MD, et al.
Published: (2025-02-01) -
Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab
by: Kelsey L. Auyeung, et al.
Published: (2024-12-01) -
GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management
by: Torsten Zuberbier, et al.
Published: (2024-11-01) -
Progress in the application of omalizumab in the treatment of chronic inducible urticaria
by: CHEN Ziyan, et al.
Published: (2024-12-01)